Cmax were within the bioequivalence limit of 0.8-1.25 and the relative bioavailability of the test formulation was 96.04 %, 97.47 % and 93.94 % for metformin, glibenclamide and pioglitazone respectively of that
taken for granted when the copy has the same quality and the same bioavailability than the original, biosimilars medicines must demonstrate comparability to the reference in terms of quality, safety
independent imatinib resistance. More recently, attention has been laid on the drug bioavailability, as a result of variation in the efflux and influx proteins, in the development of resistance